- Home
- Companies
- Antengene Corporation Limited
- Products
- Model ATG-527 - verdinexor - SINE ...
Model ATG-527 -verdinexor - SINE Compound
ATG-527 (verdinexor) is a SINE compound with a novel dual mechanism of action being developed for the treatment of viral infection. It inhibits the replication of viruses that utilize the XPO1 machinery for some aspect of their life cycle,while contributing to symptom relief via suppression of cytokine-mediated inflammatory responses. Inhibition of XPO1 does not rely on immune status for antiviral effects and may thus benefit immunocompromised patients.
Pre-clinical studies have demonstrated the broad spectrum anti-viral activity of ATG-527 (verdinexor),including against pandemic influenza strains and other viral classes,such as human immunodeficiency virus (HIV),respiratory syncytial virus (RSV),hepatitis C virus (HCV) and EBV. Pre-clinical studies also showed promising data of ATG-527 (verdinexor) in the treatment of SLE where it significantly reduced total and germinal center B cells,plasmablasts and plasma cell production in lupus mouse model.
We are in partnership with Karyopharm Therapeutics for clinical development, manufacturing and commercialization of verdinexor in Greater China (mainland China,Hong Kong,Taiwan,Macau),Australia,New Zealand,South Korea,and the ASEAN countries. We plan to conduct a Phase I/II clinical trial for the treatment of CAEBV infection and SLE.